Monoclonal Antibody Biosimilars: Examples and Clinical Uses

When you hear the word "generic," you probably think of a cheap pill that does the same thing as the brand-name drug. But when it comes to monoclonal antibody biosimilars, that simple idea doesn’t hold up. These aren’t copies in the way aspirin is a copy of a brand-name painkiller. They’re complex, living-like proteins made in living cells - and getting them right is one of the toughest challenges in modern medicine.

Think of it this way: if a small-molecule drug is like a simple key, a monoclonal antibody is like a custom-made lock with 150,000 tiny parts. Even the tiniest change in how it’s made - a shift in sugar molecules attached to the protein, or a slight twist in its 3D shape - can affect how it works in the body. That’s why biosimilars aren’t called "generics." They’re called biosimilars: highly similar, but not identical. And that’s okay, as long as they work just as safely and effectively as the original.

What Makes Monoclonal Antibody Biosimilars Different

Monoclonal antibodies are proteins designed to target specific cells in the body - like cancer cells or overactive immune cells. They’re made by growing cells in bioreactors, not by mixing chemicals in a lab. Because they’re made by living systems, no two batches are exactly alike. Even the original manufacturer can’t make the exact same molecule twice. That’s why biosimilar companies don’t need to recreate the original drug perfectly. They just need to prove their version behaves the same way in the body.

The U.S. Food and Drug Administration (FDA) says biosimilars must show "no clinically meaningful differences" in safety, purity, and potency compared to the reference product. The European Medicines Agency (EMA) agrees. Both agencies require a mountain of data: hundreds of lab tests comparing molecular structure, animal studies, and clinical trials in thousands of patients. The goal? To prove that switching from the original drug to the biosimilar won’t change outcomes.

One of the biggest technical hurdles? Glycosylation - the sugar chains attached to the antibody. A 2011 study found that some patients had allergic reactions to cetuximab because of a specific sugar structure (alpha-1,3-galactose) in the original drug. That same sugar can appear in biosimilars if the manufacturing process isn’t tightly controlled. So biosimilar makers don’t just copy the drug - they reverse-engineer the entire production system to match it.

Approved Monoclonal Antibody Biosimilars and What They Treat

As of 2023, the FDA has approved over 20 monoclonal antibody biosimilars. Here are the big ones, and the conditions they’re used for:

• Bevacizumab biosimilars (Avastin): Used for colorectal, lung, and brain cancers. Six biosimilars are approved: Mvasi, Zirabev, Alymsys, Vegzelma, Avzivi, and Jobevne.
• Rituximab biosimilars (Rituxan): Used for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Three approved: Truxima, Ruxience, and Riabni.
• Trastuzumab biosimilars (Herceptin): Used for HER2-positive breast and stomach cancers. Six approved: Ogivri, Herzuma, Ontruzant, Trazimera, Kanjinti, and Hercessi.
• Infliximab biosimilars (Remicade): Used for Crohn’s disease, ulcerative colitis, and rheumatoid arthritis. The first monoclonal antibody biosimilar ever approved - in the EU in 2013. Remsima became the first in the U.S. to be labeled "interchangeable" in July 2023.

These aren’t just lab curiosities. They’re being used in hospitals every day. A 2022 study in JAMA Oncology tracked 1,247 patients who switched from rituximab to Truxima. The results? No drop in effectiveness. No rise in side effects. And a 28% drop in cost per treatment cycle.

Why Cost Matters - And How Much Is Saved

Biosimilars aren’t cheap, but they’re significantly cheaper than the originals. The original Herceptin cost over $70,000 per year in the U.S. before biosimilars hit the market. Today, biosimilars like Ogivri and Kanjinti cost 15-30% less. That doesn’t sound like much until you multiply it by thousands of patients.

Industry analysts at Evaluate Pharma predict monoclonal antibody biosimilars will save the U.S. healthcare system $250 billion between 2023 and 2028. Bevacizumab, trastuzumab, and rituximab biosimilars will make up 78% of those savings. That’s billions of dollars that can go back into cancer care, mental health services, or just keeping premiums lower for patients.

And it’s not just about price. When biosimilars enter the market, even the original drug companies often lower their prices. That’s called the "biosimilar effect." It’s not a giveaway - it’s competition. And it’s working.

Interchangeability: The Next Big Step

There’s a special category within biosimilars called "interchangeable." That means a pharmacist can swap the biosimilar for the original drug without asking the doctor - just like they do with generic pills. In July 2023, Celltrion’s Remsima (infliximab) became the first monoclonal antibody biosimilar to get this designation from the FDA.

To qualify, a company must prove that switching back and forth between the reference product and the biosimilar doesn’t increase risk. That’s a higher bar than regular biosimilarity. It requires multiple switch studies - patients alternating between the two drugs over months - to show no drop in effectiveness or rise in side effects. It’s not easy. But once a biosimilar gets this stamp, it becomes much easier for hospitals and pharmacies to adopt it.

Challenges Still in the Way

Despite the progress, adoption isn’t automatic. Many doctors still hesitate. A 2022 survey by the American Society of Clinical Oncology found only 58% of oncologists felt "very confident" prescribing biosimilars. Some of that comes from lack of education. Some comes from fear - even though data shows they’re safe.

Patent lawsuits are another roadblock. On average, each monoclonal antibody biosimilar faces 14.7 patent challenges before it can launch. These legal battles can delay entry by years. And even when biosimilars are approved, pharmacy benefit managers (PBMs) sometimes block them from formularies unless they offer deeper discounts than the original.

Then there’s immunogenicity - the risk that the body sees the biosimilar as foreign and mounts an immune response. The EMA reported 12 cases of unexpected immune reactions across 1.2 million patient-years of exposure. That’s a rate of 0.001%. Same as the reference products. Still, it’s a concern, especially for long-term treatments like those for rheumatoid arthritis.

What’s Coming Next

The pipeline is full. As of September 2023, the FDA had 37 monoclonal antibody biosimilars in review. The biggest focus? Biosimilars for Humira (adalimumab) and Keytruda (pembrolizumab). Humira was the top-selling drug in the world for years - and its biosimilars are now entering the market. Hyrimoz, approved in late 2023, is just the beginning.

Researchers are also working on biosimilars for newer types of biologics - bispecific antibodies that target two cancer markers at once, and antibody-drug conjugates that deliver chemo directly to tumors. The EMA plans to release new guidelines for these complex products by mid-2024.

IQVIA predicts that by 2027, monoclonal antibody biosimilars will make up 35% of all biologic prescriptions in the U.S. - up from 18% in 2022. Cancer treatments will drive most of that growth, making up 62% of the volume.

Bottom Line

Monoclonal antibody biosimilars are not a future idea. They’re here. They’re used. They’re saving money. And they’re not compromising safety. If you or someone you know is on a drug like Herceptin, Rituxan, or Avastin, ask your doctor: is a biosimilar an option? The answer might be yes - and it could mean lower costs without sacrificing care.

The science behind these drugs is complex, but the outcome is simple: more patients can get life-saving treatment - and the system doesn’t have to break to make it happen.